-Colin P N Dinney Researcher Activity Profile

Research Author Detailed Information 

Colin P N Dinney Publication Rate By Year

Colin P N Dinney has published 1 paper(s) in 2002, 8 paper(s) in 2006, 35 paper(s) in 2007, 9 paper(s) in 2008, for a total of 53 research publications in total.

Colin P N Cp Dinney Author Information

LAST NAME: dinney

FIRST NAME: Colin P N

INITIALS: cp

AFFILIATION:

Papers

Colin P N Dinney's Publication Record

1. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. Year Published: 2007
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. ladam@mdanderson.org
2. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Year Published: 2007
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
3. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Year Published: 2006
Department of Cancer Biology, Brain Tumor Center, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
4. Should cystectomy only be performed at high-volume hospitals by high-volume surgeons? Year Published: 2006
Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
5. Genetic polymorphism in bladder cancer. Year Published: 2006
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. xwu@mdanderson.org
6. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. Year Published: 2006
Department of Urology, the University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
7. Matrix metalloproteinase polymorphisms and bladder cancer risk. Year Published: 2006
Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
8. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Year Published: 2007
Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA.
9. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Year Published: 2007
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Unit 1340, 1155 Pressler Boulevard, Houston, TX 77030, USA.
10. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Year Published: 2007
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
11. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Year Published: 2007
Department of Epidemiology and Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
12. Risk assessment of renal cell carcinoma using alkaline comet assay. Year Published: 2007
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
13. Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Year Published: 2007
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. pblack@mdanderson.org
14. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Year Published: 2007
Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
15. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Year Published: 2007
Division of Urology, McGill University Health Center, Montreal, Quebec, Canada.
16. Targeted therapies in bladder cancer--an update. Year Published: 2007
Department of Urology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
17. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Year Published: 2007
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
18. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. Year Published: 2007
Department of Epidemiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
19. Emerging drugs for targeted therapy of bladder cancer. Year Published: 2007
Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
20. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Year Published: 2007
Department of Epidemiology and Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
21. Interferon-alpha Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells. Year Published: 2007
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
22. Projecting individualized probabilities of developing bladder cancer in white individuals. Year Published: 2007
Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. xwu@mdanderson.org
23. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. Year Published: 2007
The Prostate Centre at Vancouver General Hospital and Department of Urologic Services, University of British Columbia, Vancouver, BC, Canada.
24. Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Year Published: 2007
Department of Urology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX, 77030, USA.
25. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. Year Published: 2007
Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA.
26. Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Year Published: 2007
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. pblack@mdanderson.org
27. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Year Published: 2007
Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
28. Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer. Year Published: 2007
Division of Urology, McGill University Health Center, Montreal, Quebec, Canada.
29. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Year Published: 2006
Department of Cancer Biology, Brain Tumor Center, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
30. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Year Published: 2007
Department of Epidemiology and Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
31. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. Year Published: 2007
Division of Urology, McGill University Health Center, Montreal, Quebec, Canada.
32. Targeted therapies in bladder cancer--an update. Year Published: 2007
Department of Urology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
33. Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. Year Published: 2007
Department of Urology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX 77030, USA.
34. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Year Published: 2007
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
35. Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC. Year Published: 2007
Corresponding author: Ashish M. Kamat, Department of Urology, Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: akamat@mdanderson.org.
36. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. Year Published: 2007
The Prostate Centre at Vancouver General Hospital and Department of Urologic Services, University of British Columbia, Vancouver, BC, Canada.
37. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. Year Published: 2007
Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA.
38. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. Year Published: 2007
Department of Urology and the Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
39. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. Year Published: 2008
Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Epidemiology and Biostatistics, Zhejiang University School of Medicine, Hangzhou 310006, China.
40. Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. Year Published: 2007
Department of Urology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX 77030, USA.
41. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Year Published: 2002
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA.
42. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Year Published: 2006
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
43. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. Year Published: 2007
Division of Urology, McGill University Health Center, Montreal, Quebec, Canada.
44. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. Year Published: 2007
Department of Urology and the Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
45. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Year Published: 2006
Department of Cancer Biology, Brain Tumor Center, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
46. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Year Published: 2008
Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1439, USA. asabichi@mdanderson.org
47. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Year Published: 2008
Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1439, USA. asabichi@mdanderson.org
48. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. Year Published: 2008
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
49. Growth factors and receptors as prognostic markers in urothelial carcinoma. Year Published: 2008
Department of Urology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit #1373, Houston, TX 77030, USA. cdinney@mdanderson.org.
50. Growth factors and receptors as prognostic markers in urothelial carcinoma. Year Published: 2008
Department of Urology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit #1373, Houston, TX 77030, USA.
51. Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer. Year Published: 2008
Departments of Epidemiology and Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and School of Public Health, Yale University School of Medicine, New Haven, Connecticut.
52. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Year Published: 2008
Authors' Affiliations: Departments of Epidemiology and Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
53. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Year Published: 2008
Department of Epidemiology and Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.